Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10

Cancer

Volumn 116, Issue SUPPL. 4, 2010, Pages 1013-1017

  Youssoufian, Hagop ^a   Rowinsky, Eric K ^a   Tonra, James ^a   Li, Yiwen ^a  

^a ImClone Systems   (United States)

Author keywords

Antibody; FMS related tyrosine kinase 3; Leukemia; Small molecule tyrosine kinase inhibitor

Indexed keywords

IMCEB 10; IMMUNOGLOBULIN ANTIBODY; LESTAURTINIB; MIDOSTAURIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IMCEB 10; MONOCLONAL ANTIBODY IMCNC 7; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TANDUTINIB; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 3; VASCULOTROPIN RECEPTOR 3 INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXICITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; GENE MUTATION; GENE OVEREXPRESSION; HEMATOPOIESIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LEUKEMIA CELL; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; T LYMPHOCYTE; WILD TYPE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; FMS-LIKE TYROSINE KINASE 3; HUMANS; IMMUNOGLOBULIN G; LEUKEMIA; MICE; MUTATION; PROTEIN KINASE INHIBITORS;

EID: 76249101596     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24787     Document Type: Conference Paper

References (25)

1. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-737.
2. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003;3:650-665.
3. Rosnet O, Schiff C, Pebusque MJ, et al. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood. 1993;82:1110-1119.
4. Adolfsson J, Mansson R, Buza-Vidas N, et al. Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment. Cell. 2005;121:295-306.
5. Mackarehtschian K, Hardin JD, Moore KA, Boast S, Goff SP, Lemischka IR. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity. 1995;3:147-161.
6. Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10:1911-1918.
7. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97:2434-2439.
8. Kelly LM, Liu Q, Kutok JL, Williams IR, Boulton CL, Gilliland DG. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood. 2002;99:310-318.
9. Kottaridis PD, Gale RE, Linch DC. Flt3 mutations and leukaemia. Br J Haematol. 2003;122:523-538.
10. Levis M, Small D. FLT3: ITDoes matter in leukemia. Leukemia. 2003;17:1738-1752.
11. Levis M, Small D. FLT3 tyrosine kinase inhibitors. Int J Hematol. 2005;82:100-107.
12. Dohner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106:3740-3746.
13. Levis M, Allebach J, Tse KF, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood. 2002;99:3885-3891.
14. Weisberg E, Boulton C, Kelly LM, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 2002;1:433-443.
15. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005;105:54-60.
16. Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood. 2004;103:3669-3676.
17. Knapper S, Burnett AK, Littlewood T, et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP-701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood. 2006;108:3262-3270.
18. Bagrintseva K, Schwab R, Kohl TM, et al. Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells. Blood. 2004;103:2266-2275.
19. Cools J, Mentens N, Furet P, et al. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res. 2004;64:6385-6389.
20. Li Y, Zhu Z. Monoclonal antibody-based therapeutics for leukemia. Expert Opin Biol Ther. 2007;7:319-330.
21. Li Y, Li H, Wang MN, et al. Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody. Blood. 2004;104:1137-1144.
22. Piloto O, Nguyen B, Huso D, et al. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples. Cancer Res. 2006;66:4843-4851.
23. Piloto O, Levis M, Huso D, et al. Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice. Cancer Res. 2005;65:1514-1522.
24. Piloto O, Wright M, Brown P, Kim KT, Levis M, Small D. Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood. 2007;109:1643-1652.
25. Li Y, Li H, Wang MN, et al. Suppression of FLT3 expressing leukemia by a monoclonal antibody-auristatin conjugate [abstract]. Blood. 2004;104:11. Abstract 1788.